Clinical laboratories have seen an increased interest in vitamin D measurements as new knowledge about the vitamin's pathobiology escalates. Clinicians now recognise that besides bone health, vitamin D insufficiency may be associated with potential health risks such as coronary artery disease, diabetes, depression, epilepsy, polycystic ovaries, musculoskeletal pain, autoimmune disease, multiple sclerosis, and cancers. While vitamin D testing and supplementation has been touted for these patients, benefit is evident only for the prevention of falls and fractures. The main form of vitamin D measured is 25-hydroxy-vitamin D (25OHD). While 25OHD assays have improved, they remain a work in progress.
INtrODUctION
There has been over 25,000 scientific articles on vitamin D since 2000 1 . A scholarly monograph on vitamin D with over 2000 pages is into its third edition 2 . An international gathering of experts on vitamin D met in March 2012 and their deliberations are available 3 . Over the last decade there has been great interest in the measurement of vitamin D given the availability of rapid automated assays for 25-hydroxy-vitamin D (25OHD). New understanding on vitamin D pathophysiology has emerged from its extra-skeletal roles. Arising from the unbridled measurements of 25OHD worldwide is the concern over the possibility of widespread inadequate vitamin D status in the population. Consequently, many guidelines and recommendations have emerged over intake of vitamin D, use of supplements, and exposure to sunlight. To understand the intense fascination with vitamin D we briefly review its new pathobiology and highlight the vagaries of 25OHD analysis.
VItAMIN D PAtHObIOLOGY Metabolism
The metabolism of vitamin D is increasingly complex [4] [5] [6] [7] [8] , but some elaboration is necessary to understand its newer actions and the vagaries of its measurement. Vitamin D exists in two forms -vitamin D2 (ergocalciferol) and vitamin D3 (cholecalciferol). Vitamin D2 is derived from ergosterol, a yeast sterol found in mushrooms. Vitamin D3 is synthesised in the skin from photodegradation of 7-dehydrocholesterol present in the suprabasal layers of the epidermis 7 . Commercially, vitamin D2 is manufactured through the ultraviolet irradiation of ergosterol, and vitamin D3 through the ultraviolet irradiation of 7-dehydrocholesterol from lanolin 9 . Both forms of vitamin D are used in fortified foods and vitamin supplements but the type of vitamin D present may differ for different products and in different countries; prescription vitamin D is often ergocalciferol. The major source of vitamin D in children and adults is dermal synthesis of vitamin D3 10, 11 . Both vitamins D2 and D3 are believed to be bioequivalent 8 , but their relative efficacy has been debated [12] [13] [14] .
Ingested vitamin D is incorporated into chylomicrons, absorbed into the lymphatic system, and enters the blood stream. Calcitriol also exerts control over its own synthesis by direct feedback inhibition on CYP27B1 activity. In addition, 1,25(OH)2D further modulates its own activity through enhancing the expression of the 24-hydroxylase, CYP24A1, which metabolises 25OHD, and 1,25(OH)2D into less active watersoluble forms. These metabolites, also bound by DBP, can circulate in substantial concentrations (ng/mL) and interfere with some of the 25OHD assays. In the failing kidney these complex renalvitamin D metabolic processes become even more complex 19, 20 .
A simplified scheme of vitamin D metabolism is given in Figure 1 below. Extraskeletal Effects VDR as well as CYP27B1 is present in most tissues and cells in the body including skin, colon, brain, pancreas, and breast as well as activated T and B lymphocytes, monocytes, and macrophages [5] [6] [7] . Thus local production of 1,25(OH)2D in these tissues from 25OHD in an autocrine or paracrine fashion may then be responsible for modulating the 200 genes 21 that govern many of the pleiotropic effects ascribed to vitamin D (e.g. cancer, cardiac, cerebrovascular, immune, pancreatic, vascular) 8, 10, [22] [23] [24] [25] . Although observational studies support a strong case for an association between vitamin D and its extra-skeletal effects, a true causal link between poor vitamin D status and these diseases has not been proven 26, 27 . Meanwhile, interest in this area is rapidly mounting. A recent comprehensive review 26 contains notable takehome messages: serum levels of 24 ng/mL of 25OHD appear beneficial for musculoskeletal health; vitamin D may have immune function as it may be involved in the pathogenesis of infections and autoimmune diseases; vitamin D deficient individuals are at increased risk of cardiovascular disorders; risk for breast and colorectal cancer decreases as serum 25OHD level increases to 30-40 ng/mL (75-100 nmol/L); all-cause mortality in the general population appears lowest at 25OHD levels ranging from 30-45 ng/mL (75-112.5 nmol/L).
An interesting report 28 has suggested that the extraneous effects of vitamin D may be related to the influence of its binding protein (DBP) concentration on serum 25OHD levels.
VItAMIN D AssAYs
Tests Commonly Included Calcium, Phosphate, Alkaline Phosphatase, Parathyroid hormone.
Specimen
Serum or plasma (ethylenediaminetetraacetic acid and heparin) are acceptable specimens for analysis.
Methodology
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Serum concentration 25OHD is the best indicator of vitamin D status as it reflects both cutaneous vitamin D3 production and dietary vitamin D (D2 and D3). In addition, it has a fairly long circulating half-life of three to four weeks. In contrast, 1,25(OH)2D has a short circulating half-life of only four hours and is a thousand-fold lower in concentration than 25OHD. Moreover, the decline in 1,25(OH)2D in vitamin D deficiency occurs late. In addition its serum levels are affected by hormones and several drugs (bisphosphonates, heparin, ketoconazole, and steroids).
Calcidiol (25-OHD) is challenging to measure accurately 33, 34 . Analytical difficulties include its hydrophobic and lipophilic nature, strong affinity to its binding protein DBP, binding to serum albumin, wide range of 25OHD concentrations in clinical samples, cross-reacting D metabolites (e.g. 24,25-dihydroxy-vitamin D, C3-epimer of 25-OHD), and assay interference from heterophilic antibodies.
Heterophilic antibodies are encountered at rates of less than 1 in 1000 clinical samples. In the original assay, 25OHD in serum is extracted from its binding proteins with an organic solvent (e.g. acetonitrile or ethanol) followed by liquid chromatography to separate 25OHD from other interfering D metabolites before entering a protein-binding assay. This procedure is timeconsuming and labour-intensive.
Several types of assays are now available for measurement of serum 25OHD, but the two most common platforms are immunoassays 35 and mass spectrometry-based 36 methods. The first automated 25OHD immunoassay (Nichols Advantage) employed DBP in a binding protein assay. This assay, beset with many problems (under-and overestimation, non-linearity, and imprecision), has been discontinued. DiaSorin and Roche introduced assays that employed specific antibodies to capture 25OHD. The DiaSorin LIAISON polyclonal antibody assay cross-reacted completely with both 25OHD3 and 25OHD2, but the Roche assay could not detect 25OHD2. While this drawback was acceptable in Europe where vitamin D2 containing supplements were rare, it was not suitable in the United States of America and the United Kingdom where vitamin D2 containing supplements were common. The Abbott ARCHITECT and Siemens Centaur have a competitive format but different modes for signal generation. The Abbott assay underestimates 25OHD2 while the SIEMENS method overestimates. Roche has launched a new total 25OHD assay, which uses recombinant DBP instead of an antibody for analyte capture. The method is standardised against liquid-chromatography tandem mass spectrometry (LC-MS/MS) with traceability to the National Institute of Standards and Technology
Proceedings of Singapore Healthcare  Volume 22  Number 3  2013 (NIST) standard reference material (SRM) 972 available since 2009. However, the new assay crossreacts with the 25-OHD-epi metabolite. There is still concern about the performance of all 25OHD assays today [37] [38] [39] [40] [41] [42] [43] . Clinical laboratories offering vitamin D as a routine service usually measure 25OHD on automated immunoassay platforms from Abbott, Roche, or Siemens that they already use for other analytes.
Some laboratories have migrated to LC-MS/MS due to local arrangements and higher reimbursement. While LC-MS/MS is generally considered the "gold standard" and a reference method is available, many laboratories do not harmonise their procedures to this standard 43 
Limitations
Clinicians should always "know their assay" and be cognizant of their limitations. Repeat testing using the same or different method should be considered if the 25OHD result is inconsistent with the clinical impression. They should be particularly aware of discrepant results in haemodialysis patients, probably due to possible matrix effects from urea Melanin in the epidermis reduces synthesis of provitamin D, with consequent lower substrate availability for 25OHD formation. Thus subjects with darker skin have lower serum 25OHD levels 47 . The Endocrine Society 5 feels that such subjects are at risk for vitamin D deficiency and should be screened for 25OHD while the Institute of Medicine disagrees. It is noteworthy that in Singapore 25OHD levels decline in proportion to skin pigmentation and gender: Chinese males > Malay males > Chinese females > Malay females > Indian males > Indian females 48 . However, the role of skin pigmentation and vitamin D is complex and needs further investigation 49 .
Obesity is also associated with low 25OHD levels, mostly because vitamin D is sequestered in adipose tissue 50 . With the growing popularity of probiotics in the modern diet, increased circulating 25OHD has been reported following oral intake of probiotics 51 .
VItAMIN D tEstING Reference Values
The desired level of serum 25OHD remains unclear, as does the dose of vitamin D needed for replacement and maintenance of optimum health. Most authorities agree that vitamin D deficiency can be defined as a 25OHD level of < 20 ng/mL 9 . When serum 25OHD levels fall below 30 ng/mL there is an associated increase in PTH signifying a relative insufficiency of vitamin D. Thus serum 25OHD > 30 ng/mL is believed to indicate vitamin D sufficiency 9 . The Endocrine Society echoed this view in its clinical practice guidelines 5 . The Institute of Medicine published dietary reference intakes for vitamin D 52 and disputed this decision limit of 30 ng/mL [53] [54] [55] prompting a firm rebuttal from the endocrinologists 56 . The two different views of vitamin D insufficiency are summarised in Table 3 (please see overleaf ).
Indications for Testing 57
Over 58 .
Despite the many diseases purported to be associated with vitamin D deficiency, randomised clinical trial data demonstrating the benefit of vitamin D supplementation only exists for the prevention of falls and fractures [59] [60] [61] . The US Preventive Services Task Force (USPSTF) has concluded that there is insufficient evidence of benefits or harm to take more than 400 IU of vitamin D3 for primary prevention of fractures in postmenopausal women. USPSTF also recommends against daily supplementation with less than 400 IU of vitamin D3 62 . Consequently, 25OHD measurement should be restricted to subjects at high risk of falls or fractures. Controversy regarding the desired therapeutic levels of 25OHD remains. Until resolved, widespread adoption of screening programmes and measurement of 25OHD even in at-risk patients may seem premature. Conclusions about causality extrapolated from observational data are tenuous 63 . While concomitant vitamin D and calcium supplements (in appropriate doses) might reduce the risk of fractures in elderly osteoporotics (diagnosed on the basis of dual energy x-ray imaging scans), routine measurement of 25OHD in these people is questionable since treatment is likely to include vitamin D supplements irrespective of the result 58 .
There is a critical need for large-scale randomised clinical trials (RCTs) to determine the role, if any, of vitamin D supplementation in extra-skeletal health outcomes. At least one such RCT is currently under way in cardiovascular disease (CVD). The Vitamin D and Omega-3 Trial is currently randomising 25,000 healthy older men and women throughout the US to receive either 2000 IU of vitamin D3 per day or placebo, as well as 1 g of omega-3 fatty acids (fish oil) per day or placebo, for five years. The primary outcomes of cancer, heart disease, and stroke will be self-reported and confirmed by medical record review 1 ; first results are expected by 2017. In the mean time more reports on vitamin D and its cardiac effects accumulate, including association of race 64 and mortality during acute coronary events 65 . A large recent meta-analysis of 12,000 deaths showed strong and independent associations of 25OHD with vascular and nonvascular mortality, thus arguing against its causal relationship to CVD 66 . , and all-cause mortality 81 . Increasing media coverage of these findings has compounded the increase in vitamin D testing and expenditure on vitamin D supplements. In light of the complexities of vitamin D pathobiology as well as the vagaries of vitamin D testing any associations between vitamin
